Amneal Pharmaceuticals and Metsera to codevelop weight loss medicines

Amneal Pharmaceuticals and Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss medicines globally. Metsera is advancing a portfolio of next-generation therapies for obesity and metabolic diseases. Metsera recently announced results from the Phase 1 clinical trial of its glucagon-like peptide-1 receptor agonist injectable, MET-097. The Phase 1 trial demonstrated that MET-097 achieved significant and durable weight loss. MET-097 is expected to be the first drug manufactured under Amneal and Metsera’s collaboration. Amneal has global product development and manufacturing capabilities, including in-house API and sterile fill-finish manufacturing, which complement Metsera’s offerings. Amneal will serve as Metsera’s preferred supply partner for developed markets, including the U.S. and Europe. Amneal will also be granted a license to commercialize Metsera’s products in select emerging markets. Amneal will construct two new greenfield manufacturing facilities in India. The new site, which will house both facilities, is expected to break ground later this year, with a total net cost to Amneal of $150M-$200M over the next four to five years. Additionally, Amneal will support Metsera with certain product development activities.